Li Yonghong, Liu Yirui, Peng Yi, Tang Jing, Li Xiaobing
Oncology. 2025 Jul 7:1-11. doi: 10.1159/000546834.
To explore effective treatment strategies for EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitors) primary resistant advanced non-small cell lung cancer (NSCLC).
We collected data on the efficacy and safety of chemotherapy combined with anlotinib in patients with EGFR-TKI primary resistant advanced NSCLC. The primary endpoints of this study were overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and treatment-related adverse events (AEs).
A total of 34 patients were enrolled. The preliminary results demonstrate that ORR and DCR of chemotherapy combined with anlotinib in patients with EGFR-TKI primary resistant advanced NSCLC were 32.35% and 64.71%, respectively. The median PFS and OS were 5 months and 9 months, respectively. In addition to efficacy, common adverse effects included myelosuppression, hypertension, proteinuria, and hand-foot syndrome. These were generally mild and well-tolerated, indicating that this regimen has promising prospects for overcoming EGFR-TKI primary resistance in advanced NSCLC.
The combination of chemotherapy and anlotinib shows promising efficacy in patients with primary EGFR TKI-resistant advanced NSCLC, with a manageable safety profile. This regimen offers a potential new treatment option for this challenging patient population. Further studies are warranted to confirm these findings and explore long-term outcomes.
探讨表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）原发性耐药的晚期非小细胞肺癌（NSCLC）的有效治疗策略。
我们收集了化疗联合安罗替尼治疗EGFR-TKI原发性耐药晚期NSCLC患者的疗效和安全性数据。本研究的主要终点为总缓解率（ORR）、无进展生存期（PFS）、疾病控制率（DCR）、总生存期（OS）以及治疗相关不良事件（AE）。
共纳入34例患者。初步结果表明，化疗联合安罗替尼治疗EGFR-TKI原发性耐药晚期NSCLC患者的ORR和DCR分别为32.35%和64.71%。中位PFS和OS分别为5个月和9个月。除疗效外，常见不良反应包括骨髓抑制、高血压、蛋白尿和手足综合征。这些不良反应一般较轻且耐受性良好，表明该治疗方案在克服晚期NSCLC的EGFR-TKI原发性耐药方面具有广阔前景。
化疗联合安罗替尼在原发性EGFR-TKI耐药的晚期NSCLC患者中显示出有前景的疗效，且安全性可控。该治疗方案为这一具有挑战性的患者群体提供了一种潜在的新治疗选择。有必要进行进一步研究以证实这些发现并探索长期疗效。
